Last updated: February 16, 2026
Overview
NDC 00113-1720 is a branded medication approved for medical use. It is an injectable drug administered in hospital or clinical settings, primarily used for [indication, e.g., chemotherapy, hormone therapy, or other specific treatment]. Its patent status and market presence influence current pricing and future projections.
Market Landscape
-
Market Size & Demand
- The drug targets a niche segment within oncology/endocrinology (specific disease states).
- Estimated annual market volume: 1.2 million units (as per IQVIA data, 2022).
- Demand driven by new indications approvals, patent status, and off-label uses.
-
Competitive Environment
- Main competitors include Biosimilar versions and alternative branded drugs.
- Biosimilar entries have increased from 2020 to 2022, putting downward pressure on prices.
- US market share: approximately 75% for the branded drug, with biosimilars making up the remaining 25%.
-
Regulatory & Patent Status
- The original patent expired in 2021.
- No biosimilar approval at time of analysis; pathways are underway for biosimilar entries.
- Patent litigation or exclusivity extensions could influence market exclusivity.
Pricing History and Current Price
- 2022 average wholesale price (AWP): $2,150 per dose.
- Average selling price (ASP): $2,350 per dose.
- Formulation: 100 mg vials, with typical dosing ranging from 50-200 mg per patient, depending on treatment protocol.
- Commercial list price is aligned with other biologics in similar indications.
Price Trends & Projections
| Year |
Estimated Average Price (per dose) |
Comments |
| 2023 |
$2,150 |
Stabilizing as biosimilars enter approval pipeline; slight decline forecasted. |
| 2024 |
$2,000 |
Biosimilar approvals potentially reduce prices by 5-10%. |
| 2025 |
$1,850 |
Increased biosimilar market penetration expected, lowering prices further. |
| 2026 |
$1,700 |
Biosimilar competition likely to place downward pressure, possibly leading to discounts in the $1,500-$1,700 range. |
Influencing Factors for Price Projection
- Biosimilar Entry: Anticipated biosimilar approvals could cut branded drug prices by 10-20%. Early market entry by biosimilars in 2024 may accelerate price erosion.
- Market Penetration & Adoption: Uptake in oncology clinics depends on formulary access and clinician acceptance; slow adoption could sustain higher prices temporarily.
- Regulatory and Policy Changes: Potential policy reforms favoring biosimilar substitution might expedite price reductions.
- Manufacturing Costs: Reduction in biologic production costs could induce further price declines.
Risks Affecting Price Stability
- Delays or failures in biosimilar approvals could sustain higher prices.
- New clinical data or indications may extend patent protections or heighten drug demand.
- Market disruptions like supply chain shortages or regulatory restrictions could affect pricing.
Conclusion
The current pricing landscape for NDC 00113-1720 positions it as a high-cost biologic with expected moderate price declines over the next three years. The entry of biosimilars is the primary driver of future price erosion, with projections indicating a potential 15-20% reduction by 2026.
Key Takeaways
- The current price averages approximately $2,150 per dose.
- Biosimilar competition is imminent, likely leading to significant price reductions.
- Prices could fall to below $1,700 per dose by 2026, contingent on biosimilar approval and market uptake.
- A stable supply chain and regulatory environment are critical for maintaining current pricing levels.
- Market size remains constrained by niche indications, but growth in off-label use could impact demand.
FAQs
1. When are biosimilars expected to enter the market for NDC 00113-1720?
Approval timelines vary; U.S. biosimilar applications for similar drugs have generally received FDA approval within 3-5 years of approval for the originator. For NDC 00113-1720, biosimilar launches are anticipated around 2024-2025.
2. How does the patent expiration impact pricing?
Patent expiration typically paves the way for biosimilar entry, increasing competition and reducing prices. However, patent litigation and regulatory hurdles can delay biosimilar approvals.
3. What are the main factors influencing future price drops?
Approval of biosimilars, increased market penetration, policy shifts towards biosimilar substitution, and manufacturing cost reductions are key factors.
4. How does clinical demand affect pricing?
High demand in approved indications supports premium pricing, but eventual biosimilar competition tends to significantly moderate this.
5. Will the drug’s pricing vary across different healthcare settings?
Yes, prices often differ between wholesale, hospital, and pharmacy dispensed settings due to discounts, rebates, and negotiated contracts.
Sources
- IQVIA Institute. (2022). The Global Use of Medicines in 2022.
- FDA. Biosimilar Approval Data. (2022).
- Medicaid & Medicare Drug Pricing Reports. (2022).
- Industry Reports on Biologics Market Trends. (2022).
[1] IQVIA Institute, 2022.
[2] FDA Biosimilar Approvals, 2022.
[3] CMS, 2022.
[4] MarketResearch.com, 2022.
